ClinicalTrials.gg
RecruitingNCT06656988PeriPREVENTUpdated Mar 23, 2026

A Contrast Medium Sparing Strategy Using Automated CO2 Injection During PVI for Prevention of Major Adverse Kidney Events (MAKE)

A Phase 3 interventional study of CO2 and Iodinated Contrast Media (ICM) in Peripheral Vascular Diseases and Kidney Diseases, sponsored by University of Leipzig. Recruiting at 11 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-23.

Sponsored by University of Leipzig · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,960
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies in Peripheral Vascular Diseases with a site in Germany — 6 open to participants now, 8 under way, 1 of them phase 3. Peripheral Vascular Diseases · Germany.

Planned enrollment
3rd of 50
1,960 · median 111
Started
2025
with 1 other
Phase 3
5 of 64
1 open now
Registered
62nd of 64
by date

Among the 64 studies in Peripheral Vascular Diseases with a site in Germany, this one is the 3rd largest by planned enrollment of the 50 interventional ones that give a count, is one of 2 that started in 2025, is one of 5 in phase 3, and was the 62nd registered.

Peripheral Vascular Diseases

443 studies on the registry are indexed under Peripheral Vascular Diseases; 44 are open to participants now.

Browse Peripheral Vascular Diseases studies →

Open to participants now

6 of the 64 studies in Peripheral Vascular Diseases with a site in Germany are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 32 Peripheral Vascular Diseases studies recruiting now, 19 (59%) set no upper age limit and 4 (13%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Peripheral Vascular Diseases with a site in Germany, or all of them as a file.
02

Study summary

The primary objective of the trial is to evaluate if an iodinated contrast medium sparing strategy using automated Carbon Dioxide (CO2) Injection prevents Major Adverse Kidney Events up to 90 days (MAKE90) in patients at moderately elevated risk for contrast-associated acute kidney injury (CA-AKI) undergoing infrainguinal peripheral vascular interventions (PVI).

Read the detailed description

PeriPREVENT is a prospective, multi-centre, controlled, open-label, 1:1 randomized superiority trial with two parallel groups.

In the intervention group patients will undergo a routine peripheral angiographic intervention (PVI) using a maximally contrast medium sparing strategy with an automated CO2 injection system including iodinated CM as bailout option in case of insufficient image quality or patient's intolerability of CO2 angiography.

The control intervention is routine PVI using iodinated contrast media (CM) as standard of care.

All patients are followed up until 12 months after the PVI.

03

Conditions studied

  • Peripheral Vascular Diseases
  • Kidney Diseases

Keywords

  • carbon dioxide
  • contrast medium
  • iodinated contrast medium
  • CA-AKI
  • angiography
  • angioplasty
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Symptomatic peripheral arterial disease presenting with either acute symptoms (Rutherford clinical categories I-IIb) or chronic symptoms (Fontaine stages IIb-IV or Rutherford clinical categories 2-6)
  2. Planned peripheral vascular intervention of infrainguinal arteries due to femoropopliteal and/or infrapopliteal lesions
  3. Increased risk of CA-AKI identified by a baseline risk score of ≥ 5 points based on a published dedicated PVI risk score and a pre-angiographic estimated (eGFR) \< 60 ml/min/1.73 m²
  4. Both angiographic strategies seem feasible at the investigator's discretion
  5. Age 18 years or older
  6. Written

Exclusion criteria

Exclusion Criteria:

  1. Very agitated patients
  2. Patients with planned full anaesthesia during procedure
  3. Patients with a life-expectancy less than one year
  4. Patients confined to bed that are completely non-ambulatory
  5. Known acute renal failure or known unstable renal function as evidenced by a recent increase in serum creatinine (SCr) of > 0.5 mg/dl or > 25% within 7 days
  6. Iodinated contrast medium exposure within 7 days prior to procedure with change in SCr ≥ 0.1 mg/dl on two SCr measures ≥ 24 h apart
  7. Advanced chronic kidney disease (CKD) with an \< 30 ml/min/1.73m² and/or dialysis
  8. Current use of nephrotoxic agents (aminoglycoside antibiotics, sulfonamides, amphotericin B, or pentamidine), or an active chemotherapy agent
  9. Acute or chronic pulmonary disease requiring oxygen therapy
  10. Patients with known patent foramen ovale or atrial septal defect
  11. Patients with planned nitrous oxide anaesthesia during intervention
  12. Patients with manifest hyperthyroidism or manifest thyrotoxicosis
  13. Known allergies or to iodinated contrast media that cannot be adequately pre-treated prior to index procedure
  14. Patients with decompensated heart failure
  15. Patients with manifest tetany
  16. Planned further procedure with a need for > 10 ml of iodinated contrast medium (CM) in any location (e.g., CT scan, coronary angiography) within a period of 90 days
  17. Any surgical procedure (except minor amputations) or intervention performed within 30 days prior to or planned within 90 days post index procedure
  18. Fertile women (within two years of their last menstruation) without appropriate measures (implanon, injections, oral contraceptives, intrauterine devices, partner with vasectomy) until day 30 after PVI.
  19. Participation in other interventional trials. Exceptions are described in the trial protocol.
  20. Suspected lack of compliance
  21. Pregnant or nursing women
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,960 participants (estimated)

Study arms

  • Active comparator
    Standard angiography using iodinated Contrast Medium (CM)

    For patients randomised in the control group, a planned infrainguinal peripheral vascular intervention (PVI, not subject to the trial) will be performed with iso-osmolar or low-osmolar iodinated CM as contrast agent. The trial sites may use iodinated CM as defined per local routine. In line with current recommendations , the use of high-osmolar CM will be prohibited in the trial.

    Drug: Iodinated Contrast Media (ICM)

  • Experimental
    Contrast medium sparing strategy using CO2 injection as contrast agent, bailout option iodinated CM

    For patients randomised in the intervention group, a planned infrainguinal peripheral vascular intervention (PVI, not subject to the trial) will be performed with CO2 as contrast agent. For the CO2 injection the Angiodroid® Injector will be used according to the recent user manual. The use of the Angiodroid® system allows a fully automatic injection with digital control. Automatic CO2 injection enhances patient tolerability as the gas injection is performed in a less explosive, more controlled manner. Iodinated CM (as described in the above section) is used as bailout option in case of inadequate image quality or intraprocedural intolerance of CO2 angiography by the patient. The reasons for use and the amount of CM must be carefully recorded.

    Drug: CO2

Interventions

  • DrugCarbon DioxideStudies of Carbon DioxideCarbon Dioxide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    CO2 will be used as contrast medium sparing strategy during peripheral angiography

    Also known as: carbon dioxide

  • DrugIodinated Contrast Media (ICM)

    Iodinated contrast medium will be used as in routine care during peripheral angiography

06

What researchers measure

Primary outcomes

  1. MAKE 90

    major adverse kidney events

    Time frame: From the day of the peripheral vascular intervention (day 0) to day 90

07

Study locations

8 of 11 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — After publication of the major results and upon reasonable request from researchers performing an individual patient data meta-analysis, individual patient data that underlie published results will be shared after de-identification. This requires approval by the local Institutional Review Board (IRB) of the researcher requesting the data along with public registration of the meta-analysis. Summary statistics that go beyond the scope of published material will be made available to researchers for meta-analysis upon reasonable request and if the necessary data analysis is not unduly time-consuming. Together with publication of the main results, the statistical analysis plan will be made publicly available. The trial protocol will be published in a medical journal as soon as possible after approval of the trial.

Supporting information: Study protocol

Time frame: The study protocol is made publicly available with the approval via CTIS.

Access criteria: Please contact the coordinating investigator.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Feb 2028, 34 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2024
First posted
Oct 24, 2024
StartActual
Apr 14, 2025
Primary completionEst.
Feb 2028
CompletionEst.
Feb 2029
Last update
Mar 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06656988
Responsible party
Sabine Steiner (Prof. Dr., University of Leipzig) — Principal investigator
First posted
Oct 24, 2024
Start date
Apr 14, 2025
Primary completion
Feb 2028 (estimated)
Completion
Feb 2029 (estimated)
Last update
Mar 23, 2026

Study contacts

Sabine Steiner, Prof Dr
Contact
angiologie@medizin.uni-leipzig.de
+493419718770
Sabine Steiner, Prof Dr
principal investigator · University Leipzig

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Carbon Dioxide

Start the discussion